

18 December 2014

Announcements
National Stock Exchange of Australia
PO Box 283
NEWCASTLE NSW 2300

Market Announcement – Development of investment fund

IQX Limited (NSX:IQX) (the Company) is pleased to announce the launch of a unique new investment fund, the **iQ Series 8 Life Science Fund (Global)** (“**iQ Series 8 Fund**”).

This milestone demonstrates the Company’s capability to develop niche investment funds comprising a select portfolio of unlisted Life Science entities. iQX Limited through its subsidiaries will manage a series of three portfolio investment funds totaling \$300 million (AUD) and investing predominantly in Australian early stage biotechnology companies. These funds will provide investors with a compelling investment opportunity and Life Science companies with a much-needed source of strategically placed investment capital.

iQX Limited Chief Executive Officer Dr George Syrmalis said, “*These funds should constitute a major driving force for the Australian biotechnology companies to the rest of the world. This is a historic milestone for Australian biotechnology where the private sector is committing so much to great Australian biotechnology companies*”.



Kelvin Boateng

Company Secretary

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQX's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQX Limited

IQX Ltd is a specialist life science investment organisation,

Sydney: 222 Clarence Street, Sydney, NSW 2000, Australia *Phone: +61 2 8239 5400 *Fax: +61 2 8362 9325
New York: 200 Park Avenue, Suite 1700, New York City, NY, USA 10166 •
London: 5 Harbour Exchange, Harbour Exchange Square, Canary Wharf E14 9GE UK•